Health and Healthcare

AstraZeneca : AZN

All AstraZeneca Articles

225 Articles

Jon C. Ogg | May 27, 2014 at 1:35 PM EDT

Pfizer’s Real Issue: Identity Crisis Against Peers

Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance…

Jon C. Ogg | May 27, 2014 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

These are the top Wall Street analyst upgrades, downgrades and initiations seen after the three-day Memorial Day weekend. They include…

Douglas A. McIntyre | May 19, 2014 at 3:11 PM EDT

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a…

Paul Ausick | May 6, 2014 at 11:05 AM EDT

Cross-Border Premium Implications in Merck-Bayer Transaction

Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced…

Paul Ausick | May 5, 2014 at 8:00 AM EDT

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower…

Paul Ausick | May 2, 2014 at 8:55 AM EDT

AstraZeneca Declares Pfizer Bid ‘Inadequate’

British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion…

Jon C. Ogg | Apr 22, 2014 at 8:35 AM EDT

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Jon C. Ogg | Mar 3, 2014 at 8:20 AM EST

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 3, 2014.…

Jon C. Ogg | Nov 19, 2013 at 12:30 PM EST

Horizon Pharma Deal Ramps Up Profitability Timeline

ThinkstockHorizon Pharma Inc. (NASDAQ: HZNP) is having a stellar day after breaking news that it entered into a pact with…

Douglas A. McIntyre | Oct 2, 2013 at 6:30 AM EDT

Big Pharma and 100,000 Jobs at Risk

ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big…

Lee Jackson | Sep 16, 2013 at 8:45 AM EDT

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the…

Trey Thoelcke | Sep 13, 2013 at 8:50 AM EDT

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact…

Jon C. Ogg | Aug 15, 2013 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Jon OggInvestors are on the hunt for solid research ideas now that stocks have pulled back a bit. 24/7 Wall…

Paul Ausick | Jul 2, 2013 at 7:35 AM EDT

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a…

1 … 8 9 10 11 12 … 15

AstraZeneca : AZN

All AstraZeneca Articles

Pfizer’s Real Issue: Identity Crisis Against Peers

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

Cross-Border Premium Implications in Merck-Bayer Transaction

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

Horizon Pharma Deal Ramps Up Profitability Timeline

Big Pharma and 100,000 Jobs at Risk

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

AstraZeneca : AZN

All AstraZeneca Articles

Pfizer’s Real Issue: Identity Crisis Against Peers

Top Analyst Upgrades and Downgrades: AMC, Cisco, NextEra, NRG, Staples and More

Pfizer Rises, AT&T Sinks to Lead the Dow’s Action

Cross-Border Premium Implications in Merck-Bayer Transaction

Pfizer Earnings Confirm Reasons for AstraZeneca Offer

AstraZeneca Declares Pfizer Bid ‘Inadequate’

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Top Analyst Upgrades and Downgrades: Apple, MarkWest, NII Holdings, RF Micro, SodaStream and More

Horizon Pharma Deal Ramps Up Profitability Timeline

Big Pharma and 100,000 Jobs at Risk

Wall Street Sees Big Biotech Making Tens of Billions in Two Critical Areas

UBS Offers Eight Well-Known International Large Cap Dividend Ruler Stocks

Top Analyst Upgrades and Downgrades: Carnival, Intel, Micron, Pulte and More

Drugmakers Pfizer, Bayer, Novartis May Join Bidding for Onyx

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

Featured Reads

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income